GTG price jumps on Applera lawsuit news
Thursday, 16 September, 2004
The share price of Genetic Technologies (ASX: GTG) jumped 25 per cent today on heavy trading after the company announced that the judge in GTG's lawsuit against Applera had ruled largely in the company's favour during the Markman hearing, in which the court rules on the precise meanings of certain disputed technical terms within GTG's patent claims.
Out of 15 disputed terms, the court ruled in favour of GTG's definition in 13 cases, and for the remaining two terms, the court adopted a definition consistent with GTG's position.
At the time of writing, GTG's shares were trading at AUD$0.475, up from a previous close of $0.38.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
